Intelomed has announced it has received FDA clearance for its CVInsight medical device, according to a news release.
CVInsight is designed to process a pulse wave through proprietary algorithms to measure and display information such as functional oxygen saturation of arterial hemoglobin (Sp02) and pulse rate of adult and pediatric patients, according to the company. It is intended to provide a utility for recording trends of pulse rate, SpO2 and the percentage of change in pulse rate and pulse strength derived from data recorded with a pulse oximeter
"We are very excited about the introduction of CVInsight," said Intelomed's CEO Frank Amoruso, in the release. "We believe it will have a meaningful impact on the ability to monitor a patient's vital signs and cardiovascular health, thereby having an extremely positive effect on the quality of patient care."
Intelomed is headquartered in Wexford, Pa.
Related Articles on FDA Clearances:
Teleflex Receives FDA Clearance for Preloaded Peripherally Inserted Central Catheter
BD Diagnostics Receives FDA Clearance for New Influenza Test
InnerOptic Receives FDA Clearance for Needle-Based Interventions 'GPS'